Chronic GVHD Clinical Trial
Official title:
SHR0302 and Prednisone as First Line Therapy for Chronic Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy of SHR0302 in combination with Prednisone as first line therapy in patients with moderate to severe chronic graft-versus-host disease (GVHD).
Treatment: Once patients are diagnosed with chronic GVHD, the combination therapy should be initiated as soon as possible. 1. Prednisone: 1mg/kg/d po. Taper steroid every two weeks according to patient's response. 2. SHR0302 QD po. for at least 28 days. Indication for stopping SHR0302 treatment: 1. No response after SHR0302 treatment for 12 weeks. 2. Develop life-threatening complication. 3. ANC<0.5×10e9/L or PLT< 30×10e9/L. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01937468 -
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04294641 -
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT05502783 -
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
|
Phase 2 | |
| Enrolling by invitation |
NCT05509582 -
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
|
Phase 2 | |
| Not yet recruiting |
NCT06458127 -
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
|
N/A | |
| Recruiting |
NCT02611180 -
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
|
||
| Completed |
NCT01106833 -
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
|
Phase 2/Phase 3 |